.The Administrative Core is responsible for the overall administration of the POI.
Our Specific Aims of the Core is to ensure that: 1) the research teams function efficiently using administrative, fiscal and scientific review procedures;2) the investigators are adherent to all pertinent regulatory practices and guidelines and adhere to the highest ethical standards in conducting their research;3)the POI investigators communicate effectively with each other, with the broader scientific and clinical communities, and other collaborators, as well as with the program sponsor, NIH. The Administrative Core coordinates the administrative, fiscal, regulatory and organizational aspects of our herpes simplex virus (HSV) research program to support the activities of the Scientific Leadership Group. Personnel in this Core will facilitate scientific communication among the clinical and laboratory sites of the projects and the investigators and staff involved in the scientific and core projects. They will prepare, oversee and maintain the IRB applications for all projects and cores;will provide fixed support services to each of the Projects and Cores;and will supervise the transport of specimens both locally and internationally to the laboratories involved in the projects. These activities involve scientific and administrative staff and facilities of the University of Washington and the Fred Hutchinson Cancer Research Center in Seattle, WA, and the Kenyatta National Hospital in Kenya. Administrative staff members in the Program bridge these institutions and have ample experience coordinating international studies. The Administrafive Core will also facilitate meetings within the POI as well as coordinate input from the Local and External Advisory ^ Committees.

Public Health Relevance

The Administrative Core will help the scientists in organizing the research activities, tracking the expenses, making sure that the research is conducted ethically, and that we have input from scientists in other institutions to make sure we achieve our goals.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-LR-M (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
United States
Zip Code
Posavad, C M; Zhao, L; Mueller, D E et al. (2015) Persistence of mucosal T-cell responses to herpes simplex virus type 2 in the female genital tract. Mucosal Immunol 8:115-26
Melvin, Ann J; Mohan, Kathleen M; Schiffer, Joshua T et al. (2015) Plasma and cerebrospinal fluid herpes simplex virus levels at diagnosis and outcome of neonatal infection. J Pediatr 166:827-33
Perti, Tara; Nyati, Mandisa; Gray, Glenda et al. (2014) Frequent genital HSV-2 shedding among women during labor in Soweto, South Africa. Infect Dis Obstet Gynecol 2014:258291
Dhankani, Varsha; Kutz, J Nathan; Schiffer, Joshua T (2014) Herpes simplex virus-2 genital tract shedding is not predictable over months or years in infected persons. PLoS Comput Biol 10:e1003922
Gantt, Soren; Cattamanchi, Ashok; Krantz, Elizabeth et al. (2014) Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy. J Clin Virol 60:127-32
Johnston, Christine; Zhu, Jia; Jing, Lichen et al. (2014) Virologic and immunologic evidence of multifocal genital herpes simplex virus 2 infection. J Virol 88:4921-31
Slyker, Jennifer; Farquhar, Carey; Atkinson, Claire et al. (2014) Compartmentalized cytomegalovirus replication and transmission in the setting of maternal HIV-1 infection. Clin Infect Dis 58:564-72
Delaney, Shani; Gardella, Carolyn; Saracino, Misty et al. (2014) Seroprevalence of herpes simplex virus type 1 and 2 among pregnant women, 1989-2010. JAMA 312:746-8
Phipps, Warren; Saracino, Misty; Selke, Stacy et al. (2014) Oral HHV-8 replication among women in Mombasa, Kenya. J Med Virol 86:1759-65
Mark, Karen E; Spruance, Spotswood; Kinghorn, George R et al. (2014) Three phase III randomized controlled trials of topical resiquimod 0.01-percent gel to reduce anogenital herpes recurrences. Antimicrob Agents Chemother 58:5016-23

Showing the most recent 10 out of 270 publications